Hari P. Miskin

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Howard A. Burris, Ian W. Flinn, Manish R. Patel et al. · The Lancet Oncology · 2018 · 205 citations

Medicine, Oncology, Pharmacology +16

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Lawrence Steinman, Edward Fox, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2022 · 199 citations

Life Sciences, Immunology, Pharmacotherapy +17

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan Fowler, Felipe Samaniego, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2021 · 161 citations · Full text

Medicine, Oncology, Pharmacology +13

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra et al. · The Lancet Haematology · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil et al. · Blood · 2019 · 87 citations · Full text

Medicine, Hematology, Oncology +13